journal
MENU ▼
Read by QxMD icon Read
search

Journal of the Advanced Practitioner in Oncology

journal
https://read.qxmd.com/read/30719397/obstructive-dysphagia-and-positional-dyspnea-can-you-identify-the-cause
#1
REVIEW
Kimberly Dotter
No abstract text is available yet for this article.
May 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30719396/enasidenib-an-oral-idh2-inhibitor-for-the-treatment-of-acute-myeloid-leukemia
#2
REVIEW
Rebecca A Myers, Scott Wirth, Sherry Williams, Patrick J Kiel
Acute myeloid leukemia (AML) is a hematologic malignancy that affects predominantly older patients, with a median age of diagnosis around 67. Overall prognosis is poor; however, novel targeted therapies that can potentially improve outcomes in these patients have emerged in recent years. Mutations in isocitrate dehydrogenase (IDH) occur in 20% of AML diagnoses. IDH2 performs a crucial role in cellular metabolism, and when this enzyme is inhibited, the cell cannot rid itself of endogenous products and is thus marked for apoptosis...
May 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30719395/an-oncology-np-md-partnership-challenges-and-rewards
#3
REVIEW
Catherine S Bishop
The State of Cancer Care in America report shines a spotlight on the significant increase of cancer survivors by 2026. One strategy to help care for the increased number of patients that require ongoing care is to hire more advanced practice providers. This article provides some keys to developing a positive, professional partnership with oncologists.
May 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30719394/clinical-management-of-pneumonitis-in-patients-receiving-anti-pd-1-pd-l1-therapy
#4
REVIEW
Justin E Bala-Hampton, Angela F Bazzell, Joyce E Dains
CASE STUDY A 48-year-old gentleman with metastatic melanoma currently receiving the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, ipilimumab (Yervoy), and the programmed cell death protein 1 (PD-1) inhibitor, nivolumab (Opdivo), returned for evaluation prior to receiving cycle 2. The patient presented with new onset dyspnea and a non-productive cough over the past week, with a temperature of 100.6°F at home on one occasion. He was placed on observation for fever, cough, and shortness of breath...
May 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30719393/management-of-advanced-bladder-cancer-an-update
#5
REVIEW
Emily A Lemke, Amishi Yogesh Shah
Bladder cancer is the sixth most common cancer in the United States; therefore, the majority of clinicians working in the oncology setting will care for this patient population. Unfortunately, treatment plans, especially in the advanced setting, lack consistency. This, along with the advanced age and comorbidities of most bladder cancer patients, can provide challenges for clinicians when developing treatment plans. In the past 2 years, new drug approvals, specifically those for immune checkpoint inhibitors, have changed the treatment landscape for bladder cancer for the first time since the 1980s...
May 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30719392/iron-overload-in-myelodysplastic-syndromes-pathophysiology-consequences-diagnosis-and-treatment
#6
REVIEW
Lindsey Lyle, Alex Hirose
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms varying in severity affecting one or more lines of hematopoiesis. Ineffective erythropoiesis results in dysregulation of iron metabolism. Most MDS patients have anemia, and some require regular red blood cell transfusions. These transfusions, in addition to factors of the disease itself, can result in iron overload (IO). Retrospective analyses suggest that MDS patients with IO have reduced overall survival and poorer outcomes following allogeneic stem cell transplant vs...
May 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30719391/feasibility-of-outpatient-high-dose-methotrexate-infusions-in-pediatric-patients-with-b-lineage-acute-lymphoblastic-leukemia
#7
REVIEW
Joy L Bartholomew, Hongying Dai, Keith J August, Robin E Ryan, Kristin A Stegenga
High-dose methotrexate (MTX) given in four hospitalizations during interim maintenance for high-risk pediatric B-lineage acute lymphocytic leukemia significantly improves survival but increases resource utilization. Children remain hospitalized for intravenous hydration and blood or urine monitoring until MTX clearance parameters are reached. Improved supportive care, extended infusion center hours, and pediatric home health expertise afford alternatives to prolonged hospital admissions, potentially offering quality, cost-effective approaches that positively impact the delivery of care...
May 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30719390/breast-cancer-and-body-image-issues
#8
EDITORIAL
Pamela Hallquist Viale
No abstract text is available yet for this article.
May 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30719389/jadpro-live-at-apsho-2017-precision-thinking-practical-knowledge
#9
EDITORIAL
Pamela Hallquist Viale
No abstract text is available yet for this article.
April 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30588359/diagnostic-snapshot-i-have-a-bad-cold
#10
REVIEW
Julie Kay Baker, Virginia L Beggs
No abstract text is available yet for this article.
March 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30588358/olaratumab-a-new-strategy-in-the-treatment-of-advanced-soft-tissue-sarcoma
#11
REVIEW
Donald C Moore, Lesli A Lavery
Olaratumab is a monoclonal antibody that recently received accelerated approval for the treatment of advanced soft-tissue sarcomas in combination with doxorubicin for a histologic subtype in which anthracycline-containing regimens is appropriate and disease is not amenable to curative surgery or radiotherapy. It inhibits platelet-derived growth factor receptor alpha, leading to the inhibition of tumor cell proliferation, angiogenesis, and metastasis. In a phase II clinical trial, olaratumab in combination with doxorubicin met its predefined primary endpoint of improving progression-free survival and secondary endpoint of overall survival compared to doxorubicin monotherapy in patients with advanced soft-tissue sarcoma...
March 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30588357/an-anecdotal-outpatient-approach-to-caring-for-patients-with-end-stage-hematologic-malignancies
#12
REVIEW
Mark Honor
Historically, hospice has been a poor option for patients with end-stage hematologic malignancies, largely due to the need for regular transfusions to sustain life near the end, and to a lesser extent the treatment of curable emergent infections. In many cases, hospice is a viable and favorable option for patients with solid tumors who are out of treatment options yet have many months to live. For patients with hematologic malignancies with fewer than 6 months to live, although tens of transfusions may be required, they may have a relatively good quality of life when those transfusions are provided...
March 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30588356/joining-forces-establishing-a-cardio-oncology-clinic
#13
REVIEW
Caroline Austin-Mattison
Patients have been surviving cancer diagnoses at a steadily increasing rate over the past few decades. Despite the encouraging decline in cancer morbidity, the cardiovascular effect of some chemotherapy medications is concerning. Moreover, even though there is extensive knowledge of the pathophysiology and increased risk of cardiotoxicity, there is a lack of specific guidelines and adequate cardio-oncology programs focused on reducing cardiovascular risks or disease in patients undergoing cancer treatment. The high incidence of both cardiovascular disease (CVD) and cancer warrants the collaboration of oncology and cardiology providers to screen and promptly treat CVD, and thereby provide an opportunity to improve cancer patients' quality of life both during treatment and extended through cancer survivorship...
March 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30588355/paraneoplastic-encephalopathy-in-a-patient-with-metastatic-lung-cancer-a-case-study
#14
REVIEW
Scott M Rowley
CASE STUDY RS, a 36-year-old female, presented to the emergency department (ED) of a large academic medical center upon the advice of her primary care provider because of 3 weeks of progressive mental status changes, weakness, and decreased oral intake. According to her husband, RS was diagnosed with stage IIIA large cell lung cancer 8 months earlier and was treated with concurrent chemotherapy (carboplatin, pemetrexed, and bevacizumab) and radiation therapy that was completed 4 months prior to admission. No other specific information about her treatment or outside health records was available...
March 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30588354/addressing-the-symptom-management-gap-in-patients-with-cancer-and-heart-failure-using-the-interactive-voice-response-system-a-pilot-study
#15
REVIEW
Anecita P Fadol, Tito R Mendoza, Daniel J Lenihan, Donna L Berry
Patients with cancer and concurrent heart failure (HF) have severe symptoms that may adversely affect patients' quality of life in addition to limiting effective anticancer therapy. A system of frequent monitoring could alert clinicians, providing the opportunity for timely intervention before patients become severely ill and require hospitalization. The purpose of this pilot study was to evaluate if the MD Anderson Symptom Inventory-Heart Failure (MDASI-HF) instrument preprogrammed via the interactive voice response system (IVRS) can be used to collect symptom data that will generate symptom alerts to providers based on preset severity levels...
March 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30588353/drug-drug-interactions-safety-and-pharmacokinetics-of-egfr-tyrosine-kinase-inhibitors-for-the-treatment-of-non-small-cell-lung-cancer
#16
REVIEW
Colleen R Kucharczuk, Alex Ganetsky, J Michael Vozniak
Inhibitors of the epidermal growth factor receptor (EGFR) are important treatment options for non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. Erlotinib, gefitinib, afatinib, and osimertinib are approved for use in NSCLC patients, and several other agents are in clinical development. The objectives of this article are to review the pharmacokinetic and known drug interaction data for EGFR tyrosine kinase inhibitors (TKIs) available for use in NSCLC patients, as well as adverse events (AEs) commonly observed with EGFR-TKI treatment, and to discuss relevant management strategies...
March 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30588352/acute-promyelocytic-leukemia-a-summary
#17
REVIEW
Meaghan M Ryan
Acute promyelocytic leukemia is a distinct subtype of acute myeloid leukemia. The disease is characterized by a chromosomal abnormality involving translocation between chromosomes 15 and 17. Current therapy has advanced to include agents such as all- trans retinoic acid and arsenic trioxide, which have improved remission and survival rates. Induction, consolidation, and maintenance regimens have now been studied and are outlined. As patients affected can develop severe bleeding complications, rapid diagnosis and initiation of appropriate treatment are vital...
March 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30588351/cardiovascular-and-cancer-risk-the-role-of-cardio-oncology
#18
REVIEW
Jessica Shank Coviello
Cardio-oncology is a subspecialty of cardiology. It was created to address oncology data indicating that newly developed drugs for cancer treatment were having unanticipated cardiac side effects. Cardio-oncology designs primary and secondary risk strategies through surveillance as well as interventions to reduce cardiovascular risk (CVR), prevent cardiotoxicities, and manage the side effects that may occur. Rather than discuss in detail the cardiotoxicities of specific therapies or radiation, this review article will explore the interplay of cancer, cancer treatment, and CVR...
March 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30588350/cardio-oncology-a-subspecialty-in-its-infancy
#19
EDITORIAL
Jessica Shank Coviello
No abstract text is available yet for this article.
March 2018: Journal of the Advanced Practitioner in Oncology
https://read.qxmd.com/read/30588349/chemotherapy-induced-nausea-and-vomiting-updates-and-recommendations
#20
EDITORIAL
Pamela Hallquist Viale
No abstract text is available yet for this article.
March 2018: Journal of the Advanced Practitioner in Oncology
journal
journal
48476
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"